Esophageal Adenocarcinoma
Early data from CAR macrophage trial show cell therapy is safe, feasible for solid tumors
Three patients have been safely treated with CT-0508, a novel cell-based therapy, according to initial results of a phase 1 trial presented at Society for the Immunotherapy of Cancer Annual Meeting.
2-year data confirm benefit of nivolumab regimen for advanced gastric, esophageal cancers
The addition of nivolumab to chemotherapy showed durable benefit for treatment-naive patients with advanced gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma, 2-year data from the CheckMate 649 study showed.
Family history of BE, esophageal adenocarcinoma links to increased risk
Preoperative pembrolizumab may enhance major pathologic response in esophageal cancer
Adding pembrolizumab to preoperative chemoradiotherapy increased major pathologic response rate compared with historical data among patients with esophageal adenocarcinoma, according to a study presented at the virtual ASCO Annual Meeting.
Q&A: non-endoscopic detection for BE, esophageal adenocarcinoma
Progress in the non-endoscopic detection for Barrett’s esophagus may lead to increased identification of those at risk for esophageal adenocarcinoma, according to opinions published in Annals of Internal Medicine.
FDA approves Opdivo for initial treatment of advanced gastrointestinal cancers
The FDA approved nivolumab as part of combination therapy for certain patients with gastrointestinal malignancies.
GERD may increase risk for cancers of the larynx, esophagus
GERD appeared to increase risk for esophageal adenocarcinoma, esophageal squamous cell carcinoma and laryngeal squamous cell carcinoma, according to results of a study published in Cancer.
Esophageal adenocarcinoma rates increase steadily among younger adults
The rate of early-onset esophageal adenocarcinoma increased an average of 2.9% per year between 1975 and 2015, according to results of a study published in Cancer Epidemiology, Biomarkers & Prevention.
Endoscopic resection can be effective in esophageal adenocarcinoma
Nivolumab regimen superior to chemotherapy alone in advanced gastric, esophageal cancers
Nivolumab plus chemotherapy increased PFS and OS compared with chemotherapy alone among previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma, study results showed.